RobertCMarabelleAHerrscherH, et al. Immunotherapy discontinuation—how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. 2020;17(11):707-715. doi:10.1038/s41571-020-0399-6
2.
NaumannRWHollebecqueAMeyerT, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37(31):2825-2834. doi:10.1200/JCO.19.00739
3.
ChaeYKCorthellLPatelSP, et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG S1609: vulvar cancers. Clin Cancer Res. 2025;31(2):308-315. doi:10.1158/1078-0432.CCR-24-1957
4.
GemelliMSalaLMorabitoA, et al. Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: final results of the I-STOP study. Eur J Cancer. 2026;237:116579. doi:10.1016/j.ejca.2026.116579
5.
ZalcmanGMadroszykAGuenziE, et al. Four-year outcomes of first-line nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced NSCLC: results of the randomized IFCT-1701 “DICIPLE” phase III trial. J Thorac Oncol. 2026;21(6):103609. doi:10.1016/j.jtho.2026.103609
6.
RobertCRibasAHamidO, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668-1674. doi:10.1200/JCO.2017.75.6270
7.
JansenYJLRozemanEAMasonR, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154-1161. doi:10.1093/annonc/mdz110
8.
Al-ShowbakiLWilsonBTamimiF, et al. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(2):e005854. doi:10.1136/jitc-2022-005854
9.
StadlerJCBelloumYDeitertB, et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 2022;82(3):349-358. doi:10.1158/0008-5472.CAN-21-1718
